• Experience of using the drug Glutoxim in patients with benign and borderline epithelial ovarian tumors after performing conservative surgical treatment

Experience of using the drug Glutoxim in patients with benign and borderline epithelial ovarian tumors after performing conservative surgical treatment

HEALTH OF WOMAN. 2018.8(134):79–86; doi 10.15574/HW.2018.134.79

Sukhanova A. A., Yegorov M. Yu.
Shupyk National Medical Academy of Postgraduate Education, Kiev

The objective: to increase the effectiveness of treatment of patients with benign and borderline epithelial ovarian tumors (EOT) after conservative operations performed based on the definition of a high risk group for recurrence and malignancy according to the molecular expression profile of the markers p53, Ki-67, estrogen receptors (ER), CD34 and E-cadherin and inclusion in the complex anti-relapse therapy of the immunomodulating drug Glutoxim.

Materials and methods. A clinical examination of 60 patients of reproductive age with EOT was performed, which were treated with organ-sparing surgical treatment (main group). Of these 60 patients, 30 women (subgroup I) were diagnosed with benign EOT (BEOT), the remaining 30 women (subgroup II) were diagnosed with borderline EOT (BoEOT) Ia and Ib stages in FIGO. In removed tumors after routine histopathological examination, the molecular profile was determined by immunohistochemically determining the protein regulator of apoptosis p53, proliferation index (PI) by Ki-67 expression, estrogen receptors — ER, microvessel density by CD34 expression and E-cadherin intercellular adhesion protein. Based on the molecular profile determination data, the removed tumor was ranked as high or low risk of recurrence and malignancy. Patients from the high-risk group for relapse and malignancy according to the molecular profile data included the immunomodulating drug Glutoxim in the complex anti-relapse therapy – intramuscularly 10 mg daily for 2 weeks with a course repeated every six months for 3 years.

The control group consisted of 64 patients with BEOT and BoEOT, who underwent conservative surgical treatment without further anti-relapse treatment.

Results. During the molecular profile study, it was found that high risk of recurrence and malignancy had EOT with p53 expression (LI ≥15%), high proliferative activity of cells with Ki-67 expression (PI ≥10%), low estrogen reception (LI ER < 49.5%), high density of microvessels on the expression of CD34 (IM ≥40 mv /mm2), low level of intercellular adhesion on the expression of E-cadherin (LI <59%). Molecular profile characterizing a high risk of recurrence and malignancy, in most cases was inherent in BoEOT.

The purpose of a comprehensive anti-relapse treatment with the inclusion of the immunomodulatory drug Glutoxim (intramuscularly daily at 10 mg for 2 weeks) after performing of sparing conservative surgical treatment with a repetition of the course every six months in patients at high risk of relapse and malignancy according to molecular profile data has reduced the relapse of EOT to 6.7% in patients of the main group compared with 20.3% in the control group during three years of follow-up observation of patients. The difference is statistically significant (p <0.05).

Conclusion. In order to prevent cases of recurrence and malignancy in patients with EOT at high risk of relapse and malignancy according to molecular profile data after a sparing surgical treatment that preserves their reproductive function, it is recommended that Glutoxim is administered in complex anti-relapse therapy at 10 mg intramuscularly per every day for 2 weeks with a repetition of the course every six months for 3 years.

Key words: benign epithelial ovarian tumors, borderline epithelial ovarian tumors, high risks of recurrence and malignancy, anti-relapse therapy, reproductive function, Glutoxim.

REFERENCES

1. Abacheva MF. (2005). Klinicheskoe znachenie interleykina-6 u bolnyih dobrokachestvennyimi i zlokachestvennyimi novoobrazovaniyami yaichnikov. Diss. kand. med. nauk. M:97.

2. Abdulaieva LM. (2010). Klinichne znachennia vyznachennia tsytokiniv u khvorykh z pukhlynamy yaiechnykiv. Likarska sprava. K. 3/4:56–59.

3. Adamyan LV, Kulakov VI, Andreeva VN. (2006). Endometriozyi. Rukovodstvo dlya vrachey. M, Meditsina:416.

4. Vihlyaeva EM, Zheleznov BI, Zaporozhan VN. (2000). Rukovodstvo po endokrinnoy ginekologii. Pod red. EM Vihlyaevoy. M, MIA:776.

5. Gataulina RG. (2003). Sostoyanie reproduktivnoy sistemyi u zhenschin s dobrokachestvennyimi opuholyami i opuholevidnyimi obrazovaniyami yaichnikov. Avtoref. dis. d-ra med. nauk 14.01.01. M:51.

6. Dmitrishen RA, Tsyigan VN, Dolgov GV. (2011). Profilaktika retsidivov dobrokachestvennyih novoobrazovaniy yaichnikov u zhenschin reproduktivnogo vozrasta posle urgentnyih operatsiy. Voenno-meditsinskiy zhurnal 332;5:36–41.

7. Dranik GN. (2006). Klinicheskaya immunologiya i allergologiya: posobie dlya studentov, vrachey-internov, immunologov, allergologov, vrachey lechebnogo profilya vseh spetsialnostey. K, OOO «Poligraf plyus»:482.

8. Dubrovina SO. (2007). Etiologiya, patogenez, profilaktika i lechenie kist yaichnikov. Avtoref. dis. d-ra med. nauk. Rostov n/D:48.

9. Ezhenedelnik «APTEKA» # 35 (356) 09.09.2002.

10. Kozhemyakin LA. (2002). Mehanizm deystviya preparata Glutoksim. Opportunisticheskie infektsii: problemyi i perspektivyi. Pod obsch. red. prof. YuV Redkina, kand. med. nauk OA Miroshnika i dokt. med. nauk VV Lobova. Omsk, Omskaya meditsinskaya akademiya:100. (c. 51–54).

11. Marchenko LA. (2009). Sovremennyie tendentsii v techenii endometrioza: klinicheskaya lektsiya. Ginekologiya 10;6 (rezhim dostupa: http://consilium-medicum.com/magazines/special/gynaecology/article).

12. Novikova EG, Battalova GYu. (2007). Pogranichnyie opuholi yaichnikov. M, OOO «Meditsinskoe informatsionnoe agentstvo»:152.

13. Nosenko EN. (2008). Nekotoryie voprosyi sovremennoy klassifikatsii, epidemiologii i patogeneza dobrokachestvennyih kistoznyih obrazovaniy yaichnikov u devochek-podrostkov i zhenschin aktivnogo reproduktivnogo vozrasta. Novosti meditsinyi i farmatsii. Ginekologiya. Elektronnyiy resurs. Rezhim dostupa: http: //www.mif-ua.com/archive/article/5992

14. Radetskaya EP. (2001). Endometrioz: patogenez i printsipyi lecheniya. Avtoref. dis. d-ra med. nauk. Minsk:36.

15. Repina NB. (2005). Kliniko-morfologicheskaya i immunogistohimicheskaya harakteristika seroznyih opuholey yaichnika. Avtoref. dis. kand. med. nauk: 14.00.14 – Onkologiya. Ryazan:20.

16. Serebrennikova KG, Kuznetsova EP. (2010). Sovremennyie predstavleniya ob etiologii i patogeneze opuholevidnyih obrazovaniy i dobrokachestvennyih opuholey yaichnikov. Saratovskiy nauchno-meditsinskiy zhurnal 6;3:552–558.

17. Urmancheeva AF, Kutusheva GF, Ulrih EA. (2012). Opuholi yaichnika (klinika, diagnostika i lechenie). SPb, Izd-vo N-L:68.

18. Yarmolinskaya MI. (2008). Tsitokinovyiy profil peritonealnoy zhidkosti i perifericheskoy krovi bolnyih s naruzhnyim genitalnyim endometriozom. Zhurnal akusherstva i zhenskih bolezney LVII;3:30–34.

19. Damak T, Ben Hassouna J, Chargui R et al. (2014, Jun). Borderline tumors of the ovary. Tunis Med. 92(6):411–416. PMid:25741843

20. Du Bois A, Ewald-Riegler N, de Gregorio N et al. (2013, May). Borderline tumours of the ovary: A cohort study of the Arbeitsgmeins­chaft Gynäkologische Onkologie (AGO) Study Group. Eur. J. Cancer. 49(8):1905–1914. https://doi.org/10.1016/j.ejca.2013.01.035; PMid:23490647

21. Naik PS, Deshmukh S, Khandeparkar SG et al. (2015). Epithelial ovarian tumors. Clinicopathological correlation and immuno­histochemical study. J. Midlife. Health 6;4:178–183. https://doi.org/10.4103/0976-7800.172349; PMid:26903759 PMCid:PMC4743281

22. Giurgea LN, Ungureanu C, Mihailovici MS. (2012). The immuno-histochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom. J. Morphol. Embryol. 53;4:967–973. PMid:23303020

23. Kozhemyakin L, Ketlinskaya O, Romanova S et al. (1999). New Generation Drugs at Treatment of Viral Hepatitis: Differentiated Effect on Normal and Virus-Infected Cells. ExConsilio. 1:59–65.

24. Longacre TA, Gilks CB. (2009). Surface epithelial stromal tumours of ovary. In: Nucci MR, Olivia E (eds), Gynecologic pathology, Elsevier Churchill Livingstone: 390–450.

25. Svintsitskiy VS, Vorobyova LI, Klymenko ES et al. (2013). Recurrence of borderline ovarian tumors. Experimental Oncology 2(35):118-121.

26. Yousef Y, Pucci V, Emil S. (2016). The Relationship between Intraoperative Rupture and Recurrence of Pediatric Ovarian Neoplasms: Preliminary Observations. J. Pediatr. Adolesc. Gynecol. 29;2:111–116. https://doi.org/10.1016/j.jpag.2015.08.002; PMid:26300232